Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
14 pending office actions • 9 clients • 14 examiners • 13 art units • 0 of 14 (0%) have an AI response strategy ready
PLEECHAE Intellectual Property LLC has 14 pending office actions in Biotechnology & Pharmaceuticals and 101 career applications. The profile reflects an active docket alongside a focused application history in biotechnology and pharmaceutical prosecution.
The resolved allowance rate is 72.22%, and the average is 2.23 office actions per allowance. The outcome rate shows that allowance was achieved in a substantial but not dominant share of resolved matters, while successful matters generally involved more than two office-action events. A client can use these figures to weigh the firm’s focused technical experience against the recorded variability in resolved prosecution outcomes.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (21%) |
| §103 only | 2 (14%) |
| §102 only | 3 (21%) |
| Double-patenting + other | 2 (14%) |
| Multi-statute (no §101) | 4 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WRUBLESKI, MATTHEW JAMES | 1 | 59.3% | +60.1% |
| WESTFALL, SARAH ANN | 1 | 5.0% | +25.0% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| STOYTCHEV, MARIN STOYTCHEV | 1 | 79.3% | +1.7% |
| MARSH, OWEN LEWIS | 1 | 66.7% | +50.0% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| TICHY, JENNIFER M.H. | 1 | 64.6% | +34.4% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17845493 | POLYIMIDE COPOLYMER AND POLYIMIDE FILM USING THE SAME | KAHN, RACHEL | 1d overdue |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 21d |
| 18678085 | METHOD FOR DETECTING SIGNS OF ATRIAL FIBRILLATION IN NORMAL SINUS RHYTHM AND DEVICE THEREOF | MARSH, OWEN LEWIS | 23d |
| 18880957 | SHUNT FOR FIBROUS ENCAPSULATION IN GLAUCOMA PATIENTS | WRUBLESKI, MATTHEW JAMES | — |
| 18879387 | APPARATUS AND METHOD FOR EVALUATING CEREBRAL AUTOREGULATION | WESTFALL, SARAH ANN | — |
| 18720849 | SMART CONTACT LENS | STOYTCHEV, MARIN STOYTCHEV | — |
| 18690418 | COMPOUND AND USE THEREOF FOR TREATING EMOTIONAL BEHAVIORAL DISORDERS | TOWNSLEY, SARA ELIZABETH | — |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18678085 | METHOD FOR DETECTING SIGNS OF ATRIAL FIBRILLATION IN NORMAL SINUS RHYTHM AND DEVICE THEREOF | MARSH, OWEN LEWIS | 23d |
| 18880957 | SHUNT FOR FIBROUS ENCAPSULATION IN GLAUCOMA PATIENTS | WRUBLESKI, MATTHEW JAMES | — |
| 18879387 | APPARATUS AND METHOD FOR EVALUATING CEREBRAL AUTOREGULATION | WESTFALL, SARAH ANN | — |
| 18872978 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES CONTAINING DEMETHYLZEYLASTERAL | HAVLIN, ROBERT H | — |
| 18690418 | COMPOUND AND USE THEREOF FOR TREATING EMOTIONAL BEHAVIORAL DISORDERS | TOWNSLEY, SARA ELIZABETH | — |
| 18580752 | PEPTIDE, COMPOSITION FOR RECOVERING RARE EARTH ELEMENTS COMPRISING SAME, AND RECOVERY METHOD | COFFA, SERGIO | — |
| 18577432 | PHARMACEUTICAL COMPOSITION FOR ALLEVIATION OR TREATMENT OF CEREBRAL INFARCTION SEQUELA | NGUYEN, NGHI V | — |
| 18577427 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VASCULAR DEMENTIA | TICHY, JENNIFER M.H. | — |
| Art Unit | Apps |
|---|---|
| 1653 | 2 |
| 3781 | 1 |
| 3791 | 1 |
| 1626 | 1 |
| 2872 | 1 |
| 3796 | 1 |
| 1629 | 1 |
| 1658 | 1 |
| 1631 | 1 |
| 1612 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18880957 | SHUNT FOR FIBROUS ENCAPSULATION IN GLAUCOMA PATIENTS | Seoul National University R&Db Foundation | WRUBLESKI, MATTHEW JAMES | 3781 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 03, 2025 |
| 18879387 | APPARATUS AND METHOD FOR EVALUATING CEREBRAL AUTOREGULATION | Seoul National University Hospital | WESTFALL, SARAH ANN | 3791 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 27, 2024 |
| 18872978 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES CONTAINING DEMETHYLZEYLASTERAL | Seoul National University R&Db Foundation | HAVLIN, ROBERT H | 1626 | §102§103§112DP | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18720849 | SMART CONTACT LENS | Opthroth Inc. | STOYTCHEV, MARIN STOYTCHEV | 2872 | §103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18678085 | METHOD FOR DETECTING SIGNS OF ATRIAL FIBRILLATION IN NORMAL SINUS RHYTHM AND DEVICE THEREOF | Chonnam National University Hospital | MARSH, OWEN LEWIS | 3796 | §101§112 | Final Rejection | 23d | Pending | May 30, 2024 |
| 18690418 | COMPOUND AND USE THEREOF FOR TREATING EMOTIONAL BEHAVIORAL DISORDERS | Neuroventi Inc. | TOWNSLEY, SARA ELIZABETH | 1629 | §102 | Final Rejection | — | Pending | Mar 08, 2024 |
| 18580752 | PEPTIDE, COMPOSITION FOR RECOVERING RARE EARTH ELEMENTS COMPRISING SAME, AND RECOVERY METHOD | Gwangju Institute of Science and Technology | COFFA, SERGIO | 1658 | §102 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18577432 | PHARMACEUTICAL COMPOSITION FOR ALLEVIATION OR TREATMENT OF CEREBRAL INFARCTION SEQUELA | Industry-University Cooperation Foundation Hanyang University | NGUYEN, NGHI V | 1653 | §103 | Final Rejection | — | Pending | Jan 08, 2024 |
| 18577427 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VASCULAR DEMENTIA | Industry-University Cooperation Foundation Hanyang University | TICHY, JENNIFER M.H. | 1653 | §103DP | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | Industry Foundation Of Chonnam National University | SCHUBERG, LAURA J | 1631 | §102 | Final Rejection | — | Pending | Oct 18, 2023 |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | Industry Foundation Of Chonnam National University | WELLES, COLMAN THOMAS | 1612 | §103§112 | Non-Final OA | 21d | Pending | Oct 02, 2023 |
| 18278468 | MAGNET ASSEMBLY FOR MOBILE TERMINAL AND WIRELESS CHARGING DEVICE COMBINED THEREWITH | Novatech Co., Ltd. | TAYLOR, APRIL ALICIA | 2876 | §102§103§112 | Non-Final OA | — | Pending | Aug 23, 2023 |
| 18024819 | PEPTIDE, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Seoul National University Hospital | CHANDRA, GYAN | 1674 | §103 | Final Rejection | — | Pending | Mar 06, 2023 |
| 17845493 | POLYIMIDE COPOLYMER AND POLYIMIDE FILM USING THE SAME | Jeonju University Office Of Industry-University Cooperation | KAHN, RACHEL | 1766 | §103§112 | Final Rejection | 1d overdue | Pending | Jun 21, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial72.2% of resolved applications prosecuted by Pleechae Intellectual Property LLC were allowed, across 101 applications in USPTO records.
2.23 office actions per allowed application on average.
14 pending office actions as of October 2026, for 9 clients, before 14 examiners in 13 art units.
